Axplora

More than 600 ADCs are currently in development worldwide — and timelines are accelerating.

As programs move faster, the need for integrated, reliable ADC manufacturing has never been greater.

Our latest investment at Le Mans 🇫🇷 strengthens our ability to support complex ADC programs with greater control, speed and predictability — from early development to commercial supply.

We’re proud to contribute to the supply chain of 6 of the 14 FDA-approved ADCs on the market today — and we continue to invest where it matters most.

🔗 Full announcement — link in bio.

🇫🇷 Honored to welcome Bruno Bonnell (SGPI) and Sébastien Jallet (Préfet de la Sarthe - ) to our Axplora Le Mans site!

We showcased our new GMP workshop — built to the highest standards for HPAPI manufacturing and supported by the investment plan — capable of producing up to 1.5 kg batches of next-gen payloads like Auristatines and Tecans, driving innovation in oncology therapies.

With 20+ years of ADC expertise, 250+ GMP batches delivered, and 6 FDA-approved ADCs, Axplora continues to power the future of oncology.